Medicine information
Uses & overview
GLIMITERIS MV1 0.2, from Steris Healthcare, is a triple-combination oral antidiabetic formulation containing Glimepiride IP 1 mg, Voglibose IP 0.2 mg, and Metformin Hydrochloride IP 500 mg. These active ingredients work through different mechanisms to support blood glucose management in adults with type 2 diabetes mellitus when the combination is considered appropriate by their treating physician. Composition Each tablet contains: Glimepiride IP: 1 mg Voglibose IP: 0.2 mg Metformin Hydrochloride IP: 500 mg Company Name: Steris Healthcare Key Product Features Triple-combination oral antidiabetic formulation. Contains Glimepiride, Voglibose, and Metformin Hydrochloride. Combines complementary mechanisms of action for blood glucose management. Intended for use under medical supervision as part of an individualized diabetes management plan. Uses of GLIMITERIS MV1 0.2 GLIMITERIS MV1 0.2 may be prescribed for adults with type 2 diabetes mellitus when the treating physician determines that this combination is appropriate for their individual treatment needs. How GLIMITERIS MV1 0.2 Works Glimepiride 1 mg: Belongs to the sulfonylurea class and stimulates insulin release from the pancreas to help lower blood glucose levels. Voglibose 0.2 mg: Inhibits intestinal alpha-glucosidase enzymes, slowing the digestion and absorption of carbohydrates and helping reduce post-meal blood glucose increases. Metformin Hydrochloride 500 mg: Helps reduce glucose production in the liver and improves the body's response to insulin. Together, these ingredients support blood glucose management through complementary mechanisms when used as prescribed. Important Safety Information GLIMITERIS MV1 0.2 is a prescription medicine and should be used only under medical supervision. Glimepiride may cause hypoglycaemia (low blood sugar), especially when meals are skipped or delayed. Voglibose may cause gastrointestinal side effects such as gas, abdominal discomfort, or diarrhoea. Metformin may cause gastrointestinal side effects and, rarely, lactic acidosis, a serious medical condition. Inform your doctor if you have kidney or liver problems, intestinal disorders, or other significant medical conditions. Tell your healthcare professional about all medicines you take, and follow recommendations for blood glucose monitoring and kidney function assessment. Disclaimer: This information is for educational purposes only and does not replace professional medical advice or the approved prescribing information. About Steris Healthcare GLIMITERIS MV1 0.2 is associated with Steris Healthcare. For verified company details, product availability, and distribution enquiries, refer to the company's official information.
How to use
Take GLIMITERIS MV1 0.2 exactly as prescribed by your doctor. Follow the recommended dose and administration instructions on the approved product information. Depending on the prescribed regimen, medicines containing Voglibose are generally taken immediately before meals, while Glimepiride is commonly taken with breakfast or the first main meal. Because this is a combination product, follow your doctor's specific instructions for timing. Maintain regular meal timings, monitor your blood glucose as advised, and do not change the dose or stop treatment without medical advice.
Storage
Store GLIMITERIS MV1 0.2 in its original packaging in a cool, dry place, away from direct sunlight and moisture. Follow the storage conditions printed on the product packaging. Keep out of reach of children and do not use the medicine after its expiry date.
